

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Caldwell Christopher A</u>			2. Issuer Name and Ticker or Trading Symbol <u>Concentrix Corp [CNXC]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) President and CEO		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>12/01/2020</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
44111 NOBEL DRIVE			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)	CA	94538						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/01/2020		J ⁽¹⁾		42,946	A	\$0	42,946	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Employee Stock Option (Right to Buy)	\$62.9 ⁽²⁾	12/01/2020		J ⁽²⁾		12,928		12/01/2020	10/07/2024	Common Stock	12,928	\$0	12,928	D	
Employee Stock Option (Right to Buy)	\$89.21 ⁽²⁾	12/01/2020		J ⁽²⁾		9,363		12/01/2020	10/06/2025	Common Stock	9,363	\$0	9,363	D	
Employee Stock Option (Right to Buy)	\$112.08 ⁽²⁾	12/01/2020		J ⁽²⁾		12,630		(3)	10/04/2026	Common Stock	12,630	\$0	12,630	D	
Employee Stock Option (Right to Buy)	\$128.67 ⁽²⁾	12/01/2020		J ⁽²⁾		11,172		(4)	10/03/2027	Common Stock	11,172	\$0	11,172	D	
Employee Stock Option (Right to Buy)	\$76.01 ⁽²⁾	12/01/2020		J ⁽²⁾		45,808		(5)	10/11/2028	Common Stock	45,808	\$0	45,808	D	
Employee Stock Option (Right to Buy)	\$110.44 ⁽²⁾	12/01/2020		J ⁽²⁾		30,057		(6)	10/02/2029	Common Stock	30,057	\$0	30,057	D	

Explanation of Responses:

- In connection with the spin-off of Concentrix Corporation ("Concentrix") by SYNnex Corporation ("SYNNEX"), on December 1, 2020, SYNnex distributed all of the issued and outstanding shares of Concentrix common stock to SYNnex stockholders (the "Distribution"). SYNnex stockholders received one share of Concentrix common stock for each share of SYNnex common stock held as of the close of business on November 17, 2020. The number of shares of Concentrix common stock reported as acquired on this Form 4 reflects the number of shares of Concentrix common stock, including shares of restricted stock, acquired by the reporting person pursuant to the Distribution.
- In connection with the spin-off of Concentrix by SYNnex and pursuant to the employee matters agreement between SYNnex and Concentrix, on December 1, 2020, each outstanding option to purchase SYNnex common stock was converted into a stock option to purchase SYNnex common stock and a stock option to purchase Concentrix common stock, in each case with respect to the same number of shares as the original SYNnex stock option. The exercise price of the converted Concentrix stock option cannot yet be determined and will be adjusted in accordance with the terms of the employee matters agreement. The exercise price set forth on this Form 4 reflects the exercise price of the original SYNnex stock option and will be updated by amendment of this Form 4 once the adjusted exercise price is known.
- The converted Concentrix stock option has the same vesting schedule as the original SYNnex stock option, which vested as to 20% of the shares on October 4, 2017, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.
- The converted Concentrix stock option has the same vesting schedule as the original SYNnex stock option, which vested as to 20% of the shares on October 3, 2018, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.
- The converted Concentrix stock option has the same vesting schedule as the original SYNnex stock option, which vested as to 20% of the shares on October 11, 2019, the first anniversary of the date of grant, and vests as to 1/60th of the shares monthly thereafter.
- The converted Concentrix stock option has the same vesting schedule as the original SYNnex stock option, which vested as to 20% of the shares on October 2, 2020, the first anniversary of the date of grant,

and vests as to 1/60th of the shares monthly thereafter.

Remarks:

/s/ Andrew A. Farwig,
Attorney-in-Fact

12/03/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.